We previously demonstrated the involvement of the tyrosine kinase receptor c-Met in medulloblastoma malignancy. The nonreceptor tyrosine kinases FAK and Pyk2, are key players in the progression of different cancers. However, their role in medulloblastoma malignancy is not well understood. In this study, using a protein array approach, we found that c-Met phosphorylates FAK and Pyk2 in medulloblastoma cells. We therefore studied the interactions between c-Met and FAK/Pyk2 and their implications for medulloblastoma therapy. We found that c-Met activates FAK and Pyk2 in several medulloblastoma cell lines. We also found that 
INTRODUCTION
Medulloblastoma is the most common brain tumor in children with an incidence of 0.6 per 100,000 patient-years according to the Central Brain Tumor Registry of the United States. It is an embryonal brain tumor that arises in the cerebellum, where it is thought to originate from primitive pluripotent precursor cells of the ventricular zone and cerebellar external germinal layer (1) . Multiple signaling pathways have been associated with medulloblastoma formation and growth. These include the developmental pathways Hedgehog (Hh), Notch, and Wnt as well as the receptor tyrosine kinases (RTK) erbB2, IGF-R and TrkC, and the oncoprotein Myc Author Manuscript Published OnlineFirst on December 21, 2011; DOI: 10.1158/1535-7163. Pyk2 are important signaling effectors linking integrins and growth factor signaling to cell adhesion, invasion, proliferation, migration, survival, and apoptosis in many cancers (10) .
Similar to FAK, which undergoes autophosphorylation at the Tyrosine 397 (Tyr 397 ) residue, autophosphorylation of Pyk2 at Tyr 402 residue leads to the recruitment of Src-family kinases, activation of extracellular signal-regulated kinase (ERKs), regulation of ion channels, cell adhesion and motility (11) . FAK expression and/or phosphorylation is elevated in a variety of cancers and frequently correlates with malignant or metastatic disease and poor patient prognosis (12) . Many studies have shown the association between FAK expression and malignancy grade, angiogenesis, invasion and migration in gliomas (13) (14) (15) In the present study, using a protein array approach, we found that c-Met stimulation by HGF phosphorylates FAK and Pyk2 in medulloblastoma cell lines. Therefore, we hypothesized that FAK/Pyk2 cooperate with c-Met-induced meduloblastoma malignancy and studied the interactions between them. We found that c-Met activates FAK and Pyk2 and that FAK and Pyk2 mediate the effects of c-Met on medulloblastoma cell migration, invasion and proliferation.
We also showed that combined targeting of c-Met and FAK could be advantageous for medulloblastoma therapy. 
MATERIALS AND METHODS

Cell culture and reagents
Three human medulloblastoma cell lines were used for this study. DAOY and ONS-76 were grown in RPMI-1640 media supplemented with 10% FBS. D425 cells were grown in Improved Modified Eagle Medium, Zinc option and 20% Fetal Bovine Serum (FBS). HGF-overexpressing DAOY cells (DAOY-HGF) were generated in our laboratory, and were cultured in Improved Modified Eagle Medium Zinc option, supplemented with 10% Fetal Bovine Serum (FBS) and the selection antibiotic Zeocin (1 μg/ml) (17) . All cells were grown at 37°C in 5% CO 2 . HGF was and PF-573228 are shown in Figure 1A . Panorama antibody microarray cell signaling kit, Cy3
and Cy5 fluorescence dyes, and all chemicals and solvents were from Sigma-Aldrich (St. Louis, MO).
Protein microarrays
Protein arrays were performed to identify cell signaling molecules that are modulated by HGF in Microarray slide for 30 min; all washes were done in PBS-Tween 0.05%. The slides were airdried before scanning with the GSI 4000 scanner, and images were generated with the Panorama software (GSI Lumonics Warwickshire, UK). The slide scanning was performed using a microarray scanner (ProScanArray Scanner, Perkin Elmer). The results were analyzed using standard median normalization between both channels Cy3 and Cy5 using the "ScanArray Express Software". All experiments were performed in triplicates.
Immunoblotting
Immunoblotting was performed using antibodies specific for phosphorylated and non- and 0.1% SDS in PBS) and lysates were collected and cleared by centrifugation. The protein concentration of the supernatant was determined, equal amounts of protein were electrophoretically separated in polyacrylamide gels, and then trans-blotted to a nitrocellulose membrane. The membrane was then incubated overnight with primary antibodies at 4ºC. The primary antibody-bound membranes were washed three times with Tween-PBS before incubation with the corresponding horseradish-conjugated secondary antibodies. After a final wash, the immunoreactive signals were detected by enhanced chemiluminescence., and quantified by densitometry on film using computer-assisted image analysis.
siRNA silencing
FAK-siRNA and Pyk2-siRNA were used to knockdown FAK and Pyk2 expressions in DAOY and D425 cells. Cells were transfected with either FAK-siRNA or Pyk2-siRNA using Oligofectamine transfection reagent according to the manufacturer's instructions. Random/scrambled siRNA (cont-siRNA) was used as a control. The knockdown of FAK and Pyk2 was confirmed by immunoblotting using the FAK and Pyk2 antibodies as described above.
Cell proliferation assays
DAOY and D425 cells were seeded in triplicates, in medium containing 10% FBS and treated with either FAK-siRNA or Pyk2-siRNA (35 nM). Controls were treated with cont-siRNA (35 nM).
Twenty-four hours later, the media was changed to low serum media (FBS 0.1%), and cells were treated with HGF (20 ng/ml). The cells were trypsinized and harvested every day, for 4 days, counted with a hemocytometer, and growth curves were established.
Migration Assays
Wound/scratch assay was performed as previously described (18) . DAOY cells were seeded at siRNA, Pyk2-siRNA, or cont-siRNA and 24 hours later treated with 20 ng/ml HGF. The cells were assessed for migration using the scratch assay. Cells that migrated into the scratch 24 hours post-treatment were photographed at 40X magnification.
Invasion assays
Transwell invasion assays were performed to determine if FAK and/or Pyk2 mediate the effects of c-Met on medulloblastoma cell invasion. Modified Boyden Chambers (Becton Dickinson, MA)
were coated with human type IV collagen (250 mg/ml). DAOY cells ( 2x10 5 ) were treated with 35 nM FAK-siRNA, Pyk2-siRNA, or cont-siRNA for 8 hours and then exposed to 20 ng/ml HGF for 24 hours. The following day, the cells were resuspended in serum-free media and added to each insert in the presence or absence of HGF 20 ng/ml. 600 µl of 10% FBS medium was placed in the lower chamber as a chemoattractant. After 8 hours of incubation at 37ºC in 5% CO 2 , invading cells were stained with 0.1% crystal violet solution and photographed at 40X. The cells were then counted under a microscope in five randomly chosen fields.
Pharmacologic inhibition of FAK and c-Met
METi was dissolved in sterile water, aliquoted, filtered, and stored in the dark, at room temperature until use. FAKi was prepared in sterile DMSO, filtered, aliquoted, and stored at - 
Statistics
All experiments were performed at least in triplicates. Numerical data were expressed as mean ± standard deviation. Two group comparisons were analyzed by two-sided Student's t test.
Multiple group comparisons were analyzed with Bonferroni/Dunn multiple comparisons tests. P Values were determined for all analyses and p<0.05 was considered significant. 
RESULTS
c-Met activates FAK and Pyk2 as revealed by protein arrays.
We assessed the effects of c-Met activation on global cell signaling in medulloblastoma cells using antibody microarrays containing 336 cell signaling molecule probes in active and total states. We found numerous changes in the activation of signal transduction proteins in response to HGF. Many of these changes were known and expected such as the induction of cyclin D1, cyclin A, and phospho-Akt by HGF. Few other changes showed effects of HGF that had not been described before in medulloblastoma (Supplementary Table 1 
Our original goal was to test the combined effects of METi and a clinically applicable FAK inhibitor on in vivo medulloblastoma growth. However, the clinically applicable FAK inhibitor is not commercially available and we were not able to obtain it from the manufacturing pharmaceutical company. We therefore assessed the effects of in vivo c-Met inhibition on medulloblastoma xenograft growth.
To test the in vivo anti-tumor properties of METi, we generated medulloblastoma xenografts by Medulloblastoma is the most common malignant brain tumor of childhood arising in the cerebellum (19) , (20) . It has the highest rates of metastasis outside the nervous system (21) (22) (23) and tends to spread hematogenously into bones, bone marrow, lymphatic nodes, liver and lungs (24, 25) . To date, surgery and radiation therapy remain the most effective treatment for medulloblastoma. However, craniospinal radiotherapy increase is frequently accompanied by life-long brain damage (20, 23) . Targeting molecular pathways that govern medulloblastoma malignancy is a promising approach for achieving future improved clinical outcomes. We identified c-Met and FAK as two such pathways that can be simultaneously targeted for greater anti-medulloblastoma effects.
FAK activation has been associated with a variety of cancers and frequently correlates with malignancy, metastasis, and poor patient prognosis (12) . A recent study has shown the involvement of integrinβ1/FAK signaling in migration and invasion in medulloblastoma (26) .
Few small molecules inhibitors of FAK have been developed. PF-562271 has shown a highly selective and potent pharmacological inhibitory effect on FAK catalytic activity, allowing it to be a first in class inhibitor reaching clinical trial testing for the cancer therapy (27) . Unfortunately, this inhibitor is not commercially available and we were unable to obtain it from the manufacturer. We therefore used the commercially available PF-573228 which cannot be used 
